Buprenorphine has partial agonist characteristics for -opioid receptors. It also possesses kappa-opioid receptor antagonistic action. It is categorized by international law as a psychoactive drug.

The hypothalamic-pituitary-adrenal or -gonadal axes may be affected by opioids. Prolactin levels in the serum are one shift that can be seen, along with cortisol and testosterone levels in the plasma. These hormonal alterations may result in the manifestation of clinical symptoms.

Natural opiates, like morphine, have distinct effects on immune system components, according to in vitro and animal research; the therapeutic significance of these results is uncertain. It is unknown if the semi-synthetic opiate buprenorphine has similar immunological effects to morphine.

Buprenorphine is continuously delivered for up to 7 days by each SOLORO® 7 buprenorphine transdermal patch. On the third day, the steady state is attained during the initial application. Buprenorphine concentrations fall after removing the patch, dropping by about 50% after 12 hours (range: 10–24 hours).

Between the indicated application areas, there are no notable differences in absorption. Each application site’s mean exposure (AUC) is within around +/- 11% of the mean exposure for the other four sites.

The active ingredient in the buprenorphine transdermal patch diffuses from the system through the skin after application.

About 96% of buprenorphine is bound to plasma proteins.

Immediately upon patch administration, there is hardly any buprenorphine metabolism in the skin. Through hepatic metabolism, buprenorphine is removed, with soluble metabolites then being excreted by the kidneys and biliary system.

The sole known active metabolite of buprenorphine is norbuprenorphine.